Visit the DSIP Category Page United States for other product formulations, including more information about the benefits of this peptide
Clinical evidence: A trial published in the New England Journal of Medicine found that tesamorelin significantly reduced visceral fat and improved lipid profiles in patients with HIV-associated abdominal fat accumulation the population in which it was studied and approved (6)
This combination makes it a so-called triple agonist , with each of these receptors involved in the regulation of metabolism, energy expenditure, and glucose homeostasis
Antioxidant Activity Molecular hydrogen selectively scavenges harmful reactive oxygen species (ROS), helping to neutralize free radicals and reduce oxidative stress without disrupting normal cell function
Through Yoo Direct Health and the YDH Training Academy, Lexi continues to push the boundaries of healthcare innovation, empowering others in the field to achieve excellence in patient care and well-being.

Why dual-pathway targeting is more effective Single pathway limitations: GLP-1 alone eventually plateaus Body compensates over time Weight loss slows after 6-12 months Some people don't respond optimally Dual pathway advantages: Harder for body to compensate Multiple redundant systems targeted Sustained weight loss longer Better for non-responders to single therapy Mechanistic synergy: Amylin + GLP-1 naturally work together Both released after meals normally Physiologic combination Not forcing unnatural state Clinical implications: Patients who plateau on semaglutide benefit from adding cagrilintide Initial combination produces maximum results May prevent or delay weight regain Better long-term outcomes Cagrilintide and semaglutide dosing protocols Proper dosing ensures maximum efficacy with manageable side effects